Nav: Home

An ounce of cancer prevention is worth a moment of your attention

November 24, 2015

What if you could visit the doctor for a blood test that predicted your personal cancer risk - then got a simple prescription that reduced that risk? The scenario isn't so far off - and bringing it closer is the goal of cancer prevention.

The global cancer burden cannot be borne by treatment alone. Prevention at every level - from diet to education, from screening to vaccination - is the key to sustainable cancer control. Now, the latest Special Issue in ecancermedicalscience hones in the three moving pieces in the above scenario - biomarkers, screening and prevention.

Screening: the combination of awareness and availability that brought you to the doctor. Biomarkers: the clues to cancer that would be present in the blood sample. And prevention: whatever that might mean for you - perhaps health, freedom, relief, time...

This Special Issue collects seven original research articles in these areas, which intersect in the underdeveloped field of cancer prevention using pharmaceutical agents. The collection is centred on broad themes, allowing the lessons within to apply beyond any particular cancer or specific agent.

Featuring an editorial from Guest Editor Prof Jack Cuzick of the Wolfson Institute of Preventive Medicine, London, UK, this unique collection of articles will provide healthcare professionals at every level with the latest in chemoprevention.

"This special issue provides an excellent focus as to where we are in the field of cancer prevention with therapeutic agents - and what needs to be done for this to have a major impact on cancer control," says Prof Cuzick.

Dr Eva Szabo of the National Cancer Institute (NCI), USA reviews the NCI programme on early stage trials to evaluate new cancer agents, and discusses the need for validated biomarkers. Her article offers an excellent and thorough review from an American perspective.

Dr Andrea DeCensi of the Ospedali Galliera, Genova, Italy and colleagues offer a perspective on breast cancer prevention - where the greatest progress in prevention research has been made, but where uptake has been limited. Both professionals and the public seem to think that preventive medicine for breast cancer isn't worth the risk of toxicity. Is this true? And can their minds be changed with evidence?

Prof Phillipe Autier of the International Agency for Research on Cancer, Lyon, France defines and addresses the risk factors and biomarkers of life-threatening cancers - after all, these are the cancers that society would most like to prevent.

ecancer editorial board member Dr Giulia Veronesi (Humanitas Research Hospital, Rozzano, Italy) and colleagues explore this topic more deeply for lung cancer - where prevention could potentially avoid progression and the need for surgery.

Dr Fabrizio Bianchi of the European Institute of Oncology, Milan, Italy develops this theme further and discusses the potential role of circulating free-micro RNAs and circulating tumour DNA as biomarkers for early lung cancer and response to treatment.

Prof Adriana Albini of IRCCS Multimedica, Milan, Italy and colleagues focus on the role of angiogenesis in the development of cancer and introduce the concept of "angioprevention." Drawing parallels between cancer and the cardiovascular system, Albini further reminds us that we can learn many lessons from the effectiveness of prevention efforts in heart disease. How can these be applied to cancer?

Prof Karen Brown and Dr Alessandro Rufini of the University of Leicester, Leicester, UK further develop this theme with a nod to chemopreventive chemicals developed or derived from dietary sources. They explore the challenges associated with translating laboratory findings to the clinic and the importance of pharmacodynamic, or predictive biomarkers for identifying candidate therapies worth taking forward into large scale randomised controlled trials.

The papers are pulled together by their united interest in identifying and overcoming barriers to acceptance of chemoprevention.

An ounce of prevention is famously said to be worth a pound of cure. It's already true in heart disease and strokes, where prevention is widely recognised - and now it's time to apply it to cancer.
Read the articles for free at


The work included in this special issue was presented at the WP2 Eurocan Platform meeting: European recommendations for biomarker-based chemoprevention trials, October 13-14, 2014, at the European Institute of Oncology, Milan, Italy.

ecancermedicalscience thanks the Experimental Cancer Medicine Centre Network, supporters of the UK Therapeutic Cancer Prevention Network, for their assistance with press materials.


Related Lung Cancer Articles:

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
Air pollution is associated with cancer mortality beyond lung cancer
A large scale epidemiological study associates some air pollutants with kidney, bladder and colorectal cancer death.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Flag and the Fury
How do you actually make change in the world? For 126 years, Mississippi has had the Confederate battle flag on their state flag, and they were the last state in the nation where that emblem remained "officially" flying.  A few days ago, that flag came down. A few days before that, it coming down would have seemed impossible. We dive into the story behind this de-flagging: a journey involving a clash of histories, designs, families, and even cheerleading. This show is a collaboration with OSM Audio. Kiese Laymon's memoir Heavy is here. And the Hospitality Flag webpage is here.